Nymox Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 1997
Revenue	0	0	0.01	0.12	0.3	Upgrade
Revenue Growth (YoY)	-	-	-95.69%	-61.20%	33.48%	Upgrade
Cost of Revenue	0	0	0	0.06	0.14	Upgrade
Gross Profit	0	0	0	0.06	0.16	Upgrade
Selling, General & Admin	2.88	5.85	3.6	6.01	4.13	Upgrade
Research & Development	3.77	6.66	8.12	7.38	6.68	Upgrade
Operating Expenses	6.65	12.5	11.72	13.38	10.8	Upgrade
Operating Income	-6.65	-12.5	-11.72	-13.33	-10.64	Upgrade
Interest Expense / Income	0.04	0.04	0.04	0.04	0.02	Upgrade
Other Expense / Income	-0.12	-0.01	-0.02	-0.2	-0.07	Upgrade
Pretax Income	-6.58	-12.54	-11.74	-13.16	-10.59	Upgrade
Net Income	-6.58	-12.54	-11.74	-13.16	-10.59	Upgrade
Shares Outstanding (Basic)	89	82	74	69	60	Upgrade
Shares Outstanding (Diluted)	89	82	74	69	60	Upgrade
Shares Change	9.04%	11.04%	7.23%	13.86%	14.85%	Upgrade
EPS (Basic)	-0.07	-0.15	-0.16	-0.19	-0.18	Upgrade
EPS (Diluted)	-0.07	-0.15	-0.16	-0.19	-0.18	Upgrade
Free Cash Flow	-5.21	-9.83	-10.05	-7.43	-7.84	Upgrade
Free Cash Flow Per Share	-0.06	-0.12	-0.14	-0.11	-0.13	Upgrade
Gross Margin	-	-	20.00%	50.00%	53.85%	Upgrade
Operating Margin	-	-	-234400.00%	-11487.07%	-3558.86%	Upgrade
Profit Margin	-	-	-234760.00%	-11346.55%	-3543.14%	Upgrade
Free Cash Flow Margin	-	-	-201000.00%	-6405.17%	-2621.07%	Upgrade
EBITDA	-6.28	-12.24	-11.43	-12.56	-10.57	Upgrade
EBITDA Margin	-	-	-228580.00%	-10826.72%	-3536.12%	Upgrade
Depreciation & Amortization	0.25	0.25	0.27	0.57	0	Upgrade
EBIT	-6.53	-12.5	-11.7	-13.12	-10.58	Upgrade
EBIT Margin	-	-	-233920.00%	-11313.79%	-3537.12%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).